Mylan NV (MYL)

43.22
NASDAQ : Health Care
Prev Close 43.22
Day Low/High 0.00 / 0.00
52 Wk Low/High 37.59 / 55.51
Avg Volume 5.15M
Exchange NASDAQ
Shares Outstanding 534.91M
Market Cap 23.02B
EPS 1.80
P/E Ratio 26.89
Div & Yield N.A. (N.A)

Latest News

Stocks Rising as Wall Street Factors In Possible September Rate Hike

Stocks Rising as Wall Street Factors In Possible September Rate Hike

Stocks rally as investors continue to analyze Federal Reserve Chair Janet Yellen's Friday speech.

Weekly Roundup: What the EpiPen Controversy Could Mean for U.S. Health Care

And how to play the fallout on related stocks.

3 Stocks That Are Too Risky to Buy Right Now -- Plus 4 More to Consider

3 Stocks That Are Too Risky to Buy Right Now -- Plus 4 More to Consider

Here's a technical look at how to trade some of the most active stocks on the market right now.

5 Winning Stocks That Could Be Ready to Drop

5 Winning Stocks That Could Be Ready to Drop

Past price action does not guarantee future price action.

More Squawk From Jim Cramer: Mylan (MYL) Became a Monopoly

More Squawk From Jim Cramer: Mylan (MYL) Became a Monopoly

Jim Cramer explains that a lack of competition is largely to blame for Mylan's (MYL) skyrocketing price of its EpiPen treatment.

Mylan to Launch Cheaper Generic Alternative to EpiPen; Shares Rise

Mylan to Launch Cheaper Generic Alternative to EpiPen; Shares Rise

The drugmaker says it will launch the product in 'several weeks' at a list price of $300 per two-park carton.

Mylan (MYL) To Offer Cheaper EpiPen Option, BloombergTV Weighs In

Mylan (MYL) To Offer Cheaper EpiPen Option, BloombergTV Weighs In

Mylan (MYL) will soon release a less expensive, generic version of its EpiPen treatment following outcry of the branded version's $600 price tag.

Mylan Lowers Prices on EpiPens But Jim Cramer Still Doesn't Like the Stock

Mylan Lowers Prices on EpiPens But Jim Cramer Still Doesn't Like the Stock

Mylan seeks to quell public outrage of its EpiPen Pricing with a generic version of the product.

Mylan Shares Jump on Discounted EpiPen Offering

Mylan Shares Jump on Discounted EpiPen Offering

The drugmaker's shares are higher after announcing the discounted allergy treatment.

Stocks Extend Gains as Wall Street Mulls Possible Rate Hike

Stocks Extend Gains as Wall Street Mulls Possible Rate Hike

U.S. stocks are rising Monday as investors continue to digest comments from top Federal Reserve officials.

CVS Drop Presents Yet Another Buying Chance

Momentum indicators are down hard, so is relative strength, while earnings were great.

U.S. Stocks Rise as Investors Weigh September Rate Hike; Mylan to Offer Generic EpiPen

U.S. Stocks Rise as Investors Weigh September Rate Hike; Mylan to Offer Generic EpiPen

U.S. stocks are higher Monday, as investors continued to digest comments on interest rates from Federal Reserve Chair Janet Yellen on Friday.

Stock Futures Flat as Investors Weigh Possible Rate Hike

Stock Futures Flat as Investors Weigh Possible Rate Hike

U.S. stock futures are trading flat Monday as investors continue to digest comments from top Federal Reserve officials on Friday.

Morning Movers: HLF, MYL, WLL, HOG

Morning Movers: HLF, MYL, WLL, HOG

Herbalife shares were climbing after Carl Icahn heated up his long-running spat with Bill Ackman.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Beat Up on the Corporations This Election Year; Market Helping Consumer: Jim Cramer's Best Blogs

Beat Up on the Corporations This Election Year; Market Helping Consumer: Jim Cramer's Best Blogs

Jim Cramer ponders the presidential campaign tradition of corporate bashing and how the stock market is more important than the Fed.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Black Rock Pharmacy Co-Owner Arthur To CNBC: 'There's a Huge Issue With PBMs'

Black Rock Pharmacy Co-Owner Arthur To CNBC: 'There's a Huge Issue With PBMs'

Pharmacy Benefit Managers (PBMs) 'operate within a sphere of secrecy,' Black Rock Pharmacy co-owner Brad Arthur told CNBC.

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco

Mylan pushed the blame for high EpiPen prices onto PBMs Thursday, causing share prices to dip. Analysts say investors were mislead.

Mylan, Trump and Tons of Huge Corporations Have Donated to the Clinton Foundation

Mylan, Trump and Tons of Huge Corporations Have Donated to the Clinton Foundation

Pretty much every company you can think of has donated to the Clinton Foundation. So has Donald Trump. Should it matter?

Trader's Daily Notebook: Is It Worth Trying to Catch a Bottom in Biotechs?

The recent harsh spotlight on the sector raises the question.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

Wall Street will look to comments from Fed Chair Janet Yellen on interest rates; futures are higher; Carl Icahn recently discussed selling his stake in Herbalife, a report says.

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.

Mylan (MYL) CEO Heather Bresch Needs To Explain EpiPen Price Hike, Senator Grassley Tells CNBC

Mylan (MYL) CEO Heather Bresch Needs To Explain EpiPen Price Hike, Senator Grassley Tells CNBC

Iowa Senator Charles Grassley said he'll have the conversation Mylan (MYL) CEO Heather Bresch has asked him for once she answers his letter.

Wall Street Hesitates Ahead of Yellen's Speech on Friday

Wall Street Hesitates Ahead of Yellen's Speech on Friday

The anticipation for Friday's speech from Federal Reserve Chair Janet Yellen left investors hesitant on Thursday.

Mylan's EpiPen Price Increase Is a Reason to Stay Clear of the Company

Mylan's EpiPen Price Increase Is a Reason to Stay Clear of the Company

The company is under public scrutiny, and has lost more than 12% of its share price so far this week.

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

Jim Cramer Explains How Mylan is Able to Get Away With High Prices on EpiPens Even in the Face of Criticism

More competition in the drug industry would prevent situations like the big price hike in Mylan's EpiPens, according to Jim Cramer.